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[s1371 Salm-Net: Investigation of international 
outbreaks of salmonellosis infection 
I.S.T. Fisher', O.N. Bill', C.L.R. Badett', B. Rowe'. 'PHLS 
Communicable Disease Surveillance Centre, London, UK, 'PHLS 
Central Publit Health hboratory, London, UK 
Objectives: To identify international outbreaks of salmonellosis and 
provide the opportunity for public health measures to be imple- 
mented. 
Method: An international network of microbiologists and epi- 
demiologists with responsibility for salmonella surveillance has been 
created as a response to the rehation of trade barriers and modern 
production practices. Multi-national distribution of products gve 
rise to the opportunity for illness to occur far b m  its source and 
a network that i s  able to exchange information rapidly can react 
effectively to an international outbreak of illness. 
Results: Sevenl international outbreaks of gastro-intestinal dis- 
ease have occurred during the time that the Salm-Net network 
has been in existence. The international extent of these has been 
identified because the network has been in place and public health 
intervention has been implemented as a result of the rapid exchange 
of information. 
Conclusion: International surveillance networks provide an 
added value to national schemes and have a c r u d  role in rapid 
case finding during outbreaks. 
IS138 I Surveillance of CreutzfeldtJacob Disease in 
Europe 
L. Chambaud. L 
No abstract available. 
Surveillance of Entemhaemom/mgic E. co/i 
(€H€Cl infection and Haemolytic Uraemic 
Syndrome (HUS) in Europe: Similar Problems - 
Similar Solutions? 
Members of the European Programme of Intervention 
Epidemiology Training (EPET), A. Ammon. Robert Koch-Institut, 
Berlin, Germany 
Objectives: To describe and compare the surveillance of E H E C  
infection and HUS in Europe in terms of 
(a) the case definitions used; 
(b) number of reported cases per year with EHEC infection or 
(c) presence of Merent s t r a i n s .  
To present a synthesis of recently investigated outbreaks in Europe. 
MethoddResults: Results of a questionnaire given to all Euro- 
pean countries re- surveillance of E H E C  and HUS will be 
presented. 
HUS; 
1 S140 1 Epidemiology of Cryptospotidiosis and 
Microsporidiosis: What Do We Know in Europe? 
R. Weber. C H  
No abstract available. 
New quinolones 
(s14T] Overview of fluoroquinolone development 
E. Rubinstein. Infernus Diseares Unit, Sheba Medical Centre, El Aviv 
University school $Medicine, El Hashomer, Israel 
Recent microbiological developments, in particular an increase in 
penicillm and macrolide resistance of Streptorocrus pneumoniae, the 
increase in resistance of Enterobacteriaceae to amikacin, the world- 
wide spread of organisms that are B-lactamase producing and this 
resistant to p-lactam antibiotics, including strains that became pro- 
ducers of, the progressive spread of methxillin-resistant Sraphylo- 
cow areus (MRSA), the increase in Shigella strains resistant to 
trimethoprim-sulfamethoxazole, the spread of multiply-drug resis- 
tant Salmonella typhi, and the treatment of infections caused by 
these pathogens. Concomitantly, the expanded safe use of the flu- 
oroquinolones in pematrics and the development of newer fluoro- 
quinolones with pronounced Gram-positive activity have broadened 
the indication list of the fluoroquinolones. Indeed most newer flu- 
oroquinolones have Gram-positive activity to a lesser or a greater 
extend and have been successfdly used in the treatment of res- 
piratory tract infections skin and soft tissue infections caused by 
Gram-positive cocci. Trodoxacin, sparfloxacin, chafioxacin, lev- 
ofloxacin SFC 222, DU-6859a, Bay 12-8039, grepafloxacin, T-3762 
and other fluoroquinolones have been clinically tested, and in ini- 
hal studies found to have clinical potenhal. Some of the fluoro- 
quinolones have, in addition, anti-anaerobic activity, which expands 
their uses. Ciprofloxacin and trovafloxacin have undergone trials in 
children and found to be associated with an acceptable rate of ad- 
verse events. Fluoroquinolones have also been recently used in the 
prophylaxis and therapy of febrile neutropenia, allowing home ther- 
apy of such patients. However, s t r a i n s  resistant to fluoroquinolones 
because ofgyrA mutations, the combination ofgyrA andgyL4 muta- 
tions associated with rapid spread of fluoroquinolones resistant strains 
threaten the future of these antibiotics. The key to the continuous 
success of these agents is dependent on successful development of 
new agents coupled with sensible use of the present agents. 
I S142 Quinolones in Community-acquired Respiratory 
J. Garau. Department $Medicine, Hospital Mhtua de T ~ ~ ~ s s Q .  
Barcelona, Spain 
The main factors in the selection of first- and second-line antibacte- 
rial agents in the management of patients with community-acquired 
respiratory tract infections include spectrum of activity against com- 
mon respiratory tract infections, blood and tissue pharmacokinet- 
ics, efficacy studies, incidence of adverse events, and dosing regi- 
mens. In the last 10-15 years, a gradual change in the antibacterial 
susceptibility of common pathogens has taken place. Penicillin re- 
sistance has emerged among pneumococci, as well as p-lactamase 
production among Haemophilus iny'luenzae and Moraxella catanalis 
being prevalent in some areas of the world. As a result, the ac- 
tivity of traditionally-used antimicrobials for respiratory infections 
has been compromised. The current limitations of &lactam and 
macrolide antibacted agents have led to a resurgence of interest 
in the use of other classes of antimicrobials in their management. 
The currently-available fluoroquinolones have been used against se- 
lected respiratory mfections with some success, but there are con- 
cerns about their efficacy against dections caused by only mod- 
erately-susceptible microorganisms, in particular pneumococci. The 
development of a number of new fluoroquinolones with enhanced 
Gram-positive activity has generated a new interests. Preliminary ex- 
perience indicates that they are effecave agents in respiratory mct 
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mfections, including Streptococcus pneumoniae, and the management of 
these infections with those agents has become a distinct possibility. 
I S143 1 Quinolones in Nosocomial Respiratory Tract 
Infections 
H. Lode. Department of Chest and Infertiow Diseases, Hospital 
HeckeshowdZehlendorj Free University Berlin, Berlin, Germany 
The newer quinolones have excellent in vitro activity against most 
of the important respiratory pathogens, such as Haemophilus in- 
juenzae, Mormella catanhalis, Staphylococcus aurarr, including m e h -  
ciUin-resistant strains,  and Enterobacteriaceae. In addition, the res- 
piratory intracellular pathogens, Legionelfa species, Mycoplasma pneu- 
moniae, Chlamydia pneumoniae, Mycobacferium tuberculosis, and Mycobac- 
terium avium-intrace~lulare, are inhibited to variable degrees, depending 
upon the strain used and the quinolone tested. 
Concerning the pharmacohnetics of newer quinolones, they usu- 
ally achieve excellent concentrations in bronchial tissue, sputum, 
alveolar lining fluid, and in alveolar macrophages, with concentra- 
tions in many cases five to ten times higher than the concomitant 
serum concentrations. 
Several recent clinical studies have demonstrated that modern 
quinolones are as active as other recently developed antibiotics, 
such as carbapenems, third- and fourth-generation cephalosporins, 
broad-spectrum p e n i d h  together with p-lactamase inhibitors, and 
combination treatments of Merent antibiotics. Initial selection of an 
antibiotic for the treatment of hospital-acquired pneumonia relies 
on assessments of disease severity, the presence of risk factors for 
specific organisms, and the time of onset of the lower respiratory 
tract infection. In a recent American Thoracic Society statement, 
quinolones occupy a leadmg place in the treatment of severe hos- 
pital-acquired pneumonia with risk factors and early onset, and in 
patients with severe hospital-acquired pneumonia with late onset. 
However, for infections induced by hlghly resistant strains, such as 
Pseudomonas aeruginosa, Acinetobacter species, and Stenotrophomonas, the 
optimal combination partner for quinolones is not yet defined. 
I S144 I The Use of Quinolones in Novel Therapeutic 
Areas 
J.-C. Pechsre. Depament  of Geneticr and Microbiology, Univmity  of 
Geneva, Genm, Switzerland 
The first quinolone antibiotics were only suitable for treating urinary 
and some gastrointestinal infections, because their activity was re- 
stricted to Gram-negative organisms, most notably the Enterobacte- 
riaceae. The last 30 years have seen the expansion of the quinolones’ 
spectra of activity. Currently adable  fluoroquinolones possess some 
activity against Gram-positive cocci, while sd displaying good ac- 
tivity against Gram-negative organisms. These agents are, however, 
s t i l l  not noted for their activity against anaerobes, and activity against 
atypical pathogens is suboptimal, thus restricting their uses against 
these organism. 
Quinolones’ pharmacokinetic properties have also evolved, al- 
though bioavailabhty remains far h m  perfect: protein binding of 
many agents is high; tissue penetration is less than ideal; and tissue 
half-lives are short. As a consequence, the fluoroquinolones cur- 
rently in use usually have to be administered more than once daily 
to achieve good clinical efficacy. 
The development of new fluoroquinolones, such as trodoxacin, 
that possess enhanced activity against pneumococci and atypical 
pathogens, means the availability of single-agent therapy for the em- 
piric treatment of moderate to severe respiratory tract infections, 
including nosocomial pneumonia. Good pneumococcal activity also 
points to the use of trodoxacin for the meatment of meningitis in 
children, especially now that concerns about arthropathy have been 
proved unfounded following experience of prolonged use of fluoro- 
quinolones in cystic fibrosis patients. Expansion of the spectrum of 
activity to include anaerobes, as well as enterobacteria, also results, 
for the first t h e ,  in a quinolone that can be confidently used for the 
treatment of intra-abdominal and pelvic infections, and in surgical 
prophylaxis. In addition, improvement of the pharmacokinetic fea- 
tures, with enhanced tissue penetration and extended tissue half-life, 
provides the added advantage of once-daily dosing. 
I S145 1 Quinolones in the Management of Sexually 
EJ. Perea. Department of Microbiology, University of Seville, Sm’lle, 
Spain 
Early-developed fluoroquinolones are only effective against gono- 
coccus, but ciprofloxacin and especially ofloxacin have broader ac- 
tivities and are also indicated for Chlamydia trachomatis, Haemophilus 
ducreyi and Mycoplasma homonis infections, and syndromes of mixed 
etiology. Also, sparffoxacin has recently been proved effective in 
treating non-gonococcal urethritis, but its phototoxicity limits its 
use. 
Many new fluoroquinolones possess in vitro activity against geni- 
tal pathogens. Trodoxacin (CP-99,219) is a new fluoroquinolone 
with excellent activity against Neisseriagonorrhoeae and is at least three 
to four times more active than other fluoroquinolones against strains 
exhibiting decreased susceptibility to ciprofloxacin. Preliminary din- 
ical stumes suggest that trodoxacin is effective in uncomplicated 
gonorrhea at a single oral dose as low as 50 mg, as well as having 
in vitro activity against C. trachomatis. At doses as low as 200 mg/day 
given for 5 days, mvailoxacin is well tolerated and effective against 
C. trachomatis infections in both men and women, and doses of 100 
and 50 mg once daily are now being evaluated 
Chical cure rates for PID appear satisfactory using ciprofloxacin 
and ofloxacin, but they lack comprehensive in vitro coverage against 
all bacterial species implicated in PID. New Centers for Disease 
Control guidelines for outpatient treatment of PID suggest that 
ofloxacin be used alongside either dindamycin or metronidazole, 
in order to provide anaerobic coverage. 
Transmitted Diseases and PID 
New aspects of anaerobic bacterial infections 
(ESCMID European Working Party on 
Antimicrobial Resistance in Anaerobic 
Bacteria) 
I S146 I Current Taxonomy and Identification of 
Anaerobic Gram-negative Bacteria 
H. Jousimies Somer. National Public Health Institute (KTL), Helsinki, 
Finland 
As a result of polyphasic taxonomic approach including 16s rRNA 
sequencing, major reorganizations among anaerobic taxa are under- 
way The gram-negative pigmented Revotella now include 7 species, 
latest inclusions being Prnigrescem (formerly part of Printermedia) and 
Fk fannerae. The non-pigmented former Mitsuokella dentalis and Hal- 
lella seregem were renamed as one species, Preuotella dentalis. Prhepari- 
nofytica and Przoogleoformans cluster withn the B$agaZis-group, but 
B.distasonis with Bforsythus among Porphyromonas. The genus Porphy- 
romonas currently includes 11 pigmented and one non-pigmented 
species; Pmtoniae (former Oribaculum catoniae). Several groups are 
